{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-250709","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2025-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.708455+00:00","generated_at":"2026-05-17T02:13:01.174344+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Coya Therapeutics prices upsized public offering of 4.18M shares at $5.50, raising ~$23M","bullets":["Offering of 3,636,364 shares (base) plus full exercise of 545,454 over-allotment, all at $5.50/share.","Gross proceeds of approximately $23.0 million; net proceeds for working capital and clinical development.","Directors and officers subject to lock-up restricting share sales until January 22, 2026.","Financial advisor to receive 100,000 warrants at $5.50 exercise price and $200,000 fee.","Lucid Capital Markets is sole book-runner; Allele Capital Partners acted as financial advisor."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-250709","json":"https://secwatch.observer/filing/0001193125-25-250709.json","markdown":"https://secwatch.observer/filing/0001193125-25-250709.md","text":"https://secwatch.observer/filing/0001193125-25-250709.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312525250709/0001193125-25-250709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312525250709/d52085d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:13:01.174344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}